Cemiplimab for skin cancer in USDecember 13, 2018
Cemiplimab-rwlc(Libtayo) injection for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) has been granted approval by USFDA.
Cemiplimab works by targeting the cellular pathway known as PD-1. By blocking this pathway, the drug may help the body’s immune system fight the cancer cells.
The safety and efficacy of Libtayo were studied in two open-label clinical trials. A total of 108 patients (75 with metastatic disease and 33 with the locally-advanced disease) were included in the efficacy evaluation.
The study’s primary endpoint was objective response rate or the percentage of patients who experienced partial shrinkage or complete disappearance of their tumor(s) after treatment.
Results showed that 47.2 per centof all patients treated with cemiplimabhad their tumoursshrink or disappear.
Cemiplimab is developed by Regeneron Pharmaceuticals, Inc